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Guest Editorial
Drug Eluting Stent: A Major Advance in Fighting Coronary Artery
Restenosis
YUK-KONG LAU
From Department of Medicine, Ruttonjee and Tang Shiu Kin Hospitals, Hong Kong
Since the first use of coronary angioplasty in 1977,
there have been major growth and development in
percutaneous coronary intervention (PCI). Due to the
advances in techniques, experiences, devices, and newer
potent antiplatelet and antithrombotic medications, PCI
is increasingly performed in highly complex and highrisk patients with a reasonably low complication rate.
Coupled with reduced discomfort, shorter hospital stay
and recovery time, it has far outnumbered the volume
of coronary artery bypass surgery. Currently, 1.7 million
PCI procedures are performed annually worldwide with
increases by 15-20% per year the last decade.
Problems in the early years of balloon angioplasty
included dissection, abrupt closure and restenosis,
the first two of which are largely controlled by
coronary stenting since early 1990's. Moreover, stents
significantly reduce coronary artery restenosis from an
average of 30-50% post balloon angioplasty to 20-30%
after stenting. Thus, stents improve the short-term
success rate and the safety of PCI. In longer term, they
decrease the restenosis and the need for repeat
revascularization. As a major breakthrough in PCI, stents
are currently widely used in about 80% of such
procedures.
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However, stenting does not eliminate restenosis.
The three major pathogenic factors in restenosis are
elastic recoil, negative arterial remodeling and
neointimal hyperplasia. Stents virtually eliminate elastic
recoil and counteract the arterial remodeling. But
neointimal hyperplasia after stenting can still cause
significant and refractory restenosis. Depending on the
pattern of in-stent restenosis, treatment with balloon
angioplasty alone is still followed by a further restenosis
in 45-55% of cases. Intravascular brachytherapy has
been used in recent years and found to be effective in
managing in-stent restenosis, but the recurrence after
brachytherapy is still in the order of 26-32%. 1-3
Moreover, the procedure itself adds extra cost, and
technical difficulty and consumes extra procedure time.
The long-term safety with the extra radiation is still
uncertain and meritorious of concern. Thus, to prevent
the development of restenosis right after PCI is a critical
issue. Enormous amount of research is being conducted
to achieve this ideal goal.
The process of neointimal hyperplasia is initiated
from the arterial injury sustained during PCI. The arterial
injury and intimal denudation trigger off inflammatory
responses. Growth factors and cytokines produced would
activate smooth muscle cell (SMC) proliferation and
migration and elicit production of extracellular matrix.
Together these processes significantly limit intra-arterial
lumen leading to restenosis. Stent-based drug delivery
to intervene this process has been developed in an
attempt to counteract this phenomenon. A number of
drugs have been studied and additional ones are being
pursued at present: anticoagulants (heparin, hirudin),
antiplatelet agents (abciximab), anti-inflammatory
drugs (dexamethasone), and antiproliferative agents
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(sirolimus, paclitaxel, actinomycin D and batimastat).
To date, the sirolimus-eluting stents appear to
demonstrate a remarkable efficacy and safety in
preventing restenosis.
Sirolimus is the generic name of Rapamycin, a
drug used in preventing renal transplant rejection. Food
and Drug Administration (FDA) in the USA had
approved this clinical use in 1999 and CE Mark in
Europe was obtained in 2000. Sirolimus is a cytostatic
agent, by virtue of cell cycle inhibition which suppresses
SMC proliferation and inflammatory cell activity. A
small fractional amount of systemtic dose of sirolimus
is incorporated into a polymer matrix surrounding a
balloon-expandable metallic stent (Bx Velocity, Cordis,
Johnson & Johnson). In vivo, the drug is released slowly
and gradually over 30 to 45 days after deployment in
the coronary artery.
The First-In-Man (FIM) study4 was a small pilot
trial involving 45 patients with de novo coronary lesions
of length <18 mm and vessel diameter 3.0-3.5 mm. All
patients were treated with an 18 mm long sirolimuseluting stent. Follow-up to 24 months revealed 0% instent restenosis and minimal neointimal hyperplasia.
There was no subacute or late stent thrombosis. Only
one patient required another PTCA at 14th month due
to new progression at a site outside the previously stented
segment.
A RAndomized double-blind study with the
sirolimus-eluting Bx VElocity balloon expandable
stent in the treatment of patients with de novo native
coronary artery Leision (RAVEL) 5 involved 238
patients from 19 centers. One hundred and twenty
patients received the sirolimus-eluting stents while
118 patients received the bare stents as control. At 6
months, there was 0% restenosis rate in the sirolimus
arm as opposed to 26% in the control arm (p<0.0001).
At 12 months, target lesion revascularization (TLR)
rate was 0% in the sirolimus group. There was no
difference in death rate and myocardial infarction
(MI) but the major adverse cardiac event (MACE)
rate was 5.8% in the sirolimus group versus 28.8%
in the control arm (p<0.0001), mainly due to the 27%
TLR rate in the latter.
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Subsequently, the results of a multicenter,
randomized double blind study of the SIRolImUScoated Bx Velocity balloon expandable stent in the
treatment of patients with de novo coronary artery
leisions (SIRIUS-400),6 were presented in May 2002.
SIRIUS involved over 1,100 patients from 53 sites in
the U.S. with half of whom received sirolimus stents.
All received 3 months of dual antiplatelet therapy
(aspirin and clopidrogrel). The patient cohort was more
complex than in RAVEL: 28% diabetes, 72%
hyperlipidemia, 42% multivessel disease, 24% Type C
lesions and 100% with a longer lesion length of 15 mm30 mm. The primary endpoint was Target Vessel Failure
(TVF: cardiac death, MI or TVR) at 9 months.
Preliminary findings of the first 400 patients showed
that the 8-months in-stent restenosis rate as assessed by
protocol-based reangiogram was reduced from 31% in
the control arm to 2% in the treated arm (p<0.001).
Independently, intravascular ultrasound confirmed a
94% reduction in neointimal hyperplasia in the sirolimus
group, as compared with control. The in-lesion (defined
as in-stent plus 5 mm proximal and distal to the stent
margin) restenosis decreased from 32.3% in the control
group to 9.2% in the sirolimus group (p<0.001). Target
lesion revascularization was reduced from 16.7% in the
control to 4.7% in the sirolimus group (a 72% reduction).
At 9-months follow-up, the event-free (from death, MI,
CABG and Re-PTCA) survival was 90.8% in the
sirolimus group versus 80.6% in the control (p=0.001).
There was no acute, subacute or late stent thrombosis in
the treatment group.
Though long-term safety beyond 2 years is still
pending, the data obtained in the last few years are
encouraging enough by the demonstrated superiority of
the sirolimus-eluting stents in significantly reducing
coronary artery restenosis and TLR. Such stent has been
approved by CE Mark in April and is available for use
in Hong Kong since May 2002.
There are other ongoing trials using sirolimuseluting stents. The E-SIRIUS trial involves 350 patients
in Europe. The C-SIRIUS trial involves 100 patients in
Canada. Another coronary bifurcation trial on 75 patients
will be completed later this year.
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However, the cost of the sirolimus-eluting stent
is substantially higher than its bare stent counterpart
by more than ten thousand Hong Kong dollars
(~US$1,300). Despite the higher initial cost, such stents
can markedly reduce the need of repeated
revascularization procedure (and potential
complications). Cost-effectiveness analysis based on
more clinical data and local patient demographics is
needed before any definite recommendation can be
made. It is likely that two groups of patients will benefit
most from using the drug eluting stents: patients with
high risk of coronary artery restenosis like diabetes,
small coronary vessel and long diffuse lesion; and
patients with high clinical risk due to restenosis such as
those with poor ventricular function and artery supplying
a large proportion of remaining viable myocardium.
Meanwhile, cardiologists should exercise clinical
judgement in individual situation and should refrain
from routine widespread use of sirolimus-eluting stents
until further health economic data of such stent are
available.
In summary, sirolimus-eluting stents represent a
major advance in our battle against coronary artery
restenosis. They will likely alter the use and approach
of PCI in managing a major cause of death in developed

J HK Coll Cardiol, Vol 10

countries including Hong Kong. Nevertheless, primary
and secondary prevention with healthy life style, exercise
and low cholesterol diet and control of smoking,
hyperlipidemia, diabetes, as well as hypertension should
be the fundamental strategy in fighting against coronary
artery disease.
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